Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiLiTing +/- Mometasone in Moderate-Severe Persistent Allergic Rhinitis
NCT05038202Phase 4Active, not recruiting
- Sponsor
- Yingu Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Bencycloquidium bromide in allergic rhinitis (AR), sponsored by Yingu Pharmaceutical Co., Ltd.. Started Jun 2021; status: active, not recruiting.
02
Drugs
Bencycloquidium bromide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05038202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038202.